CJC-1295 Made in USA — Third-Party Verified
PX1 Research provides laboratory-grade CJC-1295 synthesized in USA-based GMP-compliant facilities. Every lot undergoes rigorous analytical validation, including HPLC purity verification, ESI-MS sequence confirmation, and endotoxin screening via an independent ISO 17025 accredited laboratory.
Quick answer
PX1 Research provides laboratory-grade CJC-1295 synthesized in USA-based GMP-compliant facilities. Every lot undergoes rigorous analytical validation, including HPLC purity verification, ESI-MS sequence confirmation, and endotoxin screening via an independent ISO 17025 accredited laboratory.
Key takeaways
- [CJC-1295](/research-peptides/cjc-1295-no-dac) is a synthetic 29-amino-acid peptide derived from the native human growth hormone-releasing hormone (GHRH 1-29).
- The integrity of peptide research depends entirely on chemical purity, structural fidelity, and absolute freedom from synthesis contaminants.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) is structurally categorized based on its modification state.
- Analytical verification is fundamental to reproducible biochemical research.
Overview of CJC-1295 in Preclinical Research
CJC-1295 is a synthetic 29-amino-acid peptide derived from the native human growth hormone-releasing hormone (GHRH 1-29). In preclinical investigation, CJC-1295 functions as a selective GHRH analog, binding specifically to the GHRH receptor (GHRHR) located on anterior pituitary somatotropes. Research indicates that this binding cascade activates adenylate cyclase, resulting in elevated intracellular cyclic adenosine monophosphate (cAMP) levels and subsequent growth hormone (GH) transcription and release.
Unlike short-acting native secretagogues, CJC-1295 was structurally engineered to resist rapid enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV). By incorporating strategic amino acid substitutions at positions 2, 8, 15, and 27, the molecule exhibits substantially enhanced enzymatic resistance. In laboratory settings, researchers utilize this compound to explore sustained growth hormone release profiles and downstream insulin-like growth factor 1 (IGF-1) axis activation, particularly within cellular and animal models of tissue repair and metabolic homeostasis.
Investigators interested in examining GHRH signaling cascades can reference our comprehensive library on GHRH analogs or evaluate specific lot data via the PX1 Research catalog.
The Strategic Importance of Domestic USA Peptide Synthesis
The integrity of peptide research depends entirely on chemical purity, structural fidelity, and absolute freedom from synthesis contaminants. When sourcing peptides for sensitive in vitro assays or preclinical animal models, obtaining CJC-1295 made in USA offers distinct technical advantages over overseas manufacturing.
Domestic manufacturing within US-based facilities allows for stringent process controls throughout solid-phase peptide synthesis (SPPS). Overseas manufacturing often suffers from inconsistent cleavage parameters, inadequate trifluoroacetic acid (TFA) salt exchange, and variable storage conditions during international transit. Chemical impurities such as truncated sequences, deletion peptides, and unreacted coupling reagents can non-specifically interact with biological target sites, introducing significant experimental noise.
PX1 Research synthesizes CJC-1295 strictly within domestic USA facilities operating under GMP-compliant manufacturing protocols. This commitment ensures rigid chain-of-custody controls, minimized environmental degradation during handling, and precise batch-to-batch repeatability required for published scientific research.
Biochemical Structure and Kinetic Dynamics
CJC-1295 is structurally categorized based on its modification state. The core modified sequence, Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2, utilizes targeted substitutions to prevent metabolic cleavage. In research literature, this base molecule is frequently referred to as Modified GRF 1-29.
When combined with Drug Affinity Complex (DAC) technology, a maleimido-propionic acid linker is covalently attached to the lysine residue at the C-terminus. This linker enables the peptide to form a stable covalent bond with circulating albumin in vivo. Preclinical rodent models demonstrate that this albumin-binding capacity extends the circulating biological half-life from minutes to several days.
Preclinical studies suggest that this extended half-life alters the physiological release pattern of growth hormone. Rather than inducing rapid pulsatile GH spikes followed by baseline clearance, CJC-1295 with DAC promotes a continuous, sustained elevation of baseline GH and total circulating IGF-1. Understanding these pharmacokinetic variations allows investigators to select the appropriate analog configuration for specific experimental objectives.
Analytical Verification: HPLC, Mass Spectrometry, and Endotoxin Control
Analytical verification is fundamental to reproducible biochemical research. PX1 Research enforces strict quality control parameters before releasing any lot of CJC-1295 for laboratory distribution. Every lot undergoes independent analysis at an ISO 17025 accredited laboratory using high-performance liquid chromatography (HPLC) and electrospray ionization mass spectrometry (ESI-MS).
Reverse-phase HPLC analysis confirms chemical purity levels exceeding 99%. This process separates the target sequence from synthesized deletion sequences, stereoisomers, and organic residues. Simultaneous mass spectrometry confirms exact molecular mass matching the theoretical sequence weight of CJC-1295, verifying correct sequence order and absence of structural truncated variants.
In addition to structural purity, endotoxin contamination represents a significant threat to cell culture viability and animal model physiological response. PX1 Research subjects all domestic batches to Chromogenic Recombinant Factor C (rFC) or LAL endotoxin testing, ensuring limits remain strictly below 0.1 EU/mg. Investigators can inspect lot-specific Certificate of Analysis documentation directly through our purity standards portal.
Comparative Analysis: CJC-1295 vs. Sermorelin, Tesamorelin, and Ipamorelin
In secretagogue and GHRH research, selecting the optimal target peptide depends on the kinetic and receptor profiles required by the experimental model. Comparing CJC-1295 against related compounds highlights key operational distinctions across the growth hormone axis.
CJC-1295 provides a extended signaling window due to its resistance against DPP-IV enzymatic degradation. In contrast, Sermorelin represents the unmodified 29-amino-acid native sequence, displaying a rapid biological half-life (approx. 10–12 minutes) and requiring short-interval observation windows. Meanwhile, Tesamorelin features a trans-3-hexenoic acid modification attached to the N-terminus, engineered specifically to enhance stability while prioritizing hepatic IGF-1 expression and lipolytic gene transcription in metabolic models.
When examining synergistic signaling cascades, researchers often combine GHRH analogs with selective growth hormone secretagogue receptor (GHSR-1a) agonists. For instance, co-administering CJC-1295 with Ipamorelin in preclinical models demonstrates a dual-receptor activation effect. While CJC-1295 stimulates the GHRH receptor pathway, Ipamorelin selectively targets the ghrelin/GHSR receptor, producing amplified GH secretion without elevating baseline cortisol or prolactin levels in rodent subjects.
Preclinical Applications in Tissue Repair and Metabolic Research
In vitro data and preclinical rodent models indicate that sustained GH and downstream IGF-1 elevation play critical roles in cellular proliferation, protein synthesis, and extracellular matrix remodeling. Consequently, CJC-1295 is extensively investigated across diverse physiological paradigms.
In connective tissue and musculoskeletal research, preclinical studies suggest that CJC-1295-mediated IGF-1 upregulation enhances collagen mRNA expression and accelerates tenocyte cellular migration. In vitro models utilizing fibroblast cultures demonstrate accelerated scratch-closure rates when exposed to media enriched with secretagogue-stimulated growth factors.
Furthermore, animal models evaluating metabolic homeostasis demonstrate that sustained GHRH pathway activation influences nitrogen retention, fatty acid beta-oxidation, and lean tissue preservation during catabolic states. These biochemical observations position CJC-1295 as a vital candidate for investigating cellular repair mechanisms, age-related endocrine decline models, and structural tissue synthesis.
Laboratory Reconstitution and Storage Parameters
To preserve the structural stability of lyophilized CJC-1295, laboratory personnel must follow standard peptide handling protocols. Upon arrival, lyophilized vials should be kept in a cold, dark environment—ideally maintained at -20°C for long-term storage or 2°C to 8°C for short-term handling.
For reconstitution, use high-grade bacteriostatic water containing 0.9% benzyl alcohol to prevent microbial growth during multi-use laboratory sampling. Reconstitution should be performed by gently running the diluent down the glass inner wall of the vial, followed by gentle swirling. Direct physical agitation or vigorous shaking must be avoided to prevent peptide shear stress and aggregation.
Once reconstituted, liquid solutions should be stored at 2°C to 8°C and evaluated within a defined experimental timeframe. Repeated freeze-thaw cycles degrade the primary peptide chain and must be avoided. Detailed technical guidelines on reconstituted handling can be accessed via our research resource library.
Domestic Supply Chain, Shipping, and Institutional Sourcing
PX1 Research prioritizes supply chain security and immediate dispatch for academic, clinical, and private research laboratories across the United States. All products are stored in climate-controlled domestic distribution hubs located in California and Arizona.
Orders placed before standard daily cutoffs are dispatched same-day via expedited domestic logistics, minimizing transit time and eliminating heat-exposure risks associated with prolonged transit. Vials are packaged in specialized protective containers to preserve chemical integrity throughout transport.
For academic institutions, biotechnology organizations, and high-volume laboratories, PX1 Research provides scalable procurement solutions. Qualified institutions seeking custom batch volumes or dedicated supply schedules can consult our wholesale portal to establish recurring supply lines backed by full analytical transparency.
Frequently Asked Questions
What is CJC-1295 and what is its primary mechanism in preclinical research?
CJC-1295 is a synthetic 29-amino-acid GHRH analog designed to bind to the GHRH receptor on pituitary somatotropes. Its primary mechanism involves activating adenylate cyclase, raising intracellular cAMP, and stimulating the synthesis and secretion of growth hormone (GH) and downstream IGF-1.
Why is domestic USA synthesis significant for CJC-1295 research samples?
Domestic synthesis in US-based GMP-compliant facilities guarantees strict control over solid-phase synthesis reagents, precise TFA salt exchange, and rigorous purification processes. This eliminates sequence deletions, heavy metal contamination, and degradation common in unverified overseas manufacturing.
How does PX1 Research verify the purity and identity of CJC-1295?
Every lot of CJC-1295 undergoes independent testing at an ISO 17025 accredited laboratory. Testing includes high-performance liquid chromatography (HPLC) to verify >99% purity, electrospray ionization mass spectrometry (ESI-MS) for sequence confirmation, and rFC/LAL assays for endotoxin quantification.
What is the primary operational difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC incorporates a maleimido-propionic acid linker that covalently binds to circulating albumin, extending its biological half-life to several days and producing continuous GH elevation. CJC-1295 without DAC (Modified GRF 1-29) lacks this linker, resulting in a shorter half-life and shorter GH release windows.
What endotoxin limits are established for PX1 Research CJC-1295?
PX1 Research enforces a strict endotoxin threshold of < 0.1 EU/mg for all laboratory research peptides. This guarantees suitability for sensitive cell culture studies and in vivo animal models without triggering non-specific inflammatory responses.
How should lyophilized CJC-1295 be stored upon arrival at the laboratory?
Lyophilized CJC-1295 should be stored in a dark, dry environment at -20°C for long-term stability. If reconstituted for active laboratory experiments, the solution must be kept at 2°C to 8°C and protected from repeated freeze-thaw cycles.
How does CJC-1295 compare to other GHRH analogs like Sermorelin?
While Sermorelin matches the native short-acting 29-amino-acid structure with a rapid half-life, CJC-1295 includes four specific amino acid substitutions that grant resistance against DPP-IV enzymatic cleavage, providing significantly extended circulating stability.
Are bulk ordering options available for research institutions?
Yes. Institutional buyers and commercial laboratories requiring larger lot sizes or recurring shipments can submit inquiries through the PX1 Research wholesale portal for volume quotes and lot reservation.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.